



Investor Contact:
Stephanie Carrington
The Ruth Group
(646) 536 -7017
scarrington@theruthgroup.com

Media Contacts:
Aaron Estrada / Amy Wheeler
The Ruth Group
(646) 536 -7028 / 7025
aestrada@theruthgroup.com /
awheeler@theruthgroup.com

CORNERSTONE PHARMACEUTICALS APPOINTS DR. SIM FASS AND HOWARD JONAS TO BOARD OF DIRECTORS

Respected leaders bring pharmaceutical and business expertise to the Board

CRANBURY, NEW JERSEY (April 30, 2013) – Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Dr. Sim Fass and Mr. Howard Jonas have been appointed to its Board of Directors. Dr. Fass is the former Chairman and Chief Executive Officer of Savient Pharmaceuticals, Inc. (NASDAQ: SVNT). Mr. Jonas is the founder and Chairman of the Board of IDT Corporation (NYSE: IDT) and Genie Energy Ltd. (NYSE: GNE), and a Cornerstone investor.

Robert Shorr, Ph.D., Cornerstone's Chief Executive Officer, stated, "Cornerstone is very pleased with the appointment of Dr. Fass and Mr. Jonas to our Board of Directors. Dr. Fass brings nearly four decades of wisdom and experience in the pharmaceutical industry to Cornerstone, which will give our company insights how best to develop our anticancer technologies for clinical success. Mr. Jonas is a respected and most capable entrepreneur in diverse fields of technology, and Cornerstone shall definitely benefit by having someone of his business acumen guiding our strategy."

Dr. Fass has 35 years of senior pharmaceutical management experience. He retired from Savient Pharmaceuticals (SVNT; formerly Bio-Technology General Corp) after a 21 year tenure in which he served as President/CEO from 1984-1997 and as CEO/Chairman from 1997-2004. Dr. Fass was also Vice President and General Manager of Wampole Laboratories, a division of Carter Wallace focusing on diagnostics of infectious diseases, immune-related disorders and reproduction. He has also held a number of marketing, sales and senior management positions at Pfizer, Inc in both pharmaceuticals and diagnostics. He has served as Director of Nanovibronix since 2005 and as Director of Novelos Therapeutics, Inc from 2005 to 2011. He received a BS degree in biology and chemistry from Yeshiva College and a doctoral degree in developmental biology/biochemistry from the Massachusetts Institute of Technology.

Mr. Jonas has extensive leadership in multiple public companies. He founded IDT Corporation, a publicly traded company with a billion dollars in revenue, in August 1990 and currently serves as Chairman and CEO. Mr. Jonas is also founder and Chairman of Genie Energy Ltd., which was spun off from IDT in 2011. The author of two books, Mr. Jonas holds a B.A. in Economics from Harvard University.



About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated.

www.cornerstonepharma.com

###

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.